Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 238Carcinoma, Non-Small-Cell Lung 205Prostatic Neoplasms 137Lung Neoplasms 96Stomach Neoplasms 85Head and Neck Neoplasms 58Squamous Cell Carcinoma of Head and Neck 57Neoplasms 42Neoplasm Metastasis 39Esophageal Neoplasms 36Ovarian Neoplasms 29Pancreatic Neoplasms 27Sarcoma 19Urinary Bladder Neoplasms 18Adenocarcinoma of Lung 18Carcinoma, Squamous Cell 17Triple Negative Breast Neoplasms 15Nasopharyngeal Carcinoma 14Adenocarcinoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma Of Esophagus 13Recurrence 12Inflammatory Breast Neoplasms 10Carcinoma, Transitional Cell 10Breast Neoplasms, Male 10Esophageal Squamous Cell Carcinoma 9Laryngeal Neoplasms 8Uterine Cervical Neoplasms 7Nasopharyngeal Neoplasms 7Leiomyosarcoma 7

Interventions

enzalutamide 3testosterone 17 beta-cypionate 2darolutamide 2abiraterone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1pamiparib 1olaparib 1lactitol 1fluciclovine F-18 1enfortumab vedotin 1cabazitaxel 1avelumab 1Standard of Care 1Selegiline 1Prednisolone 1Pluvicto 1PSMA-617 1Gonadotropin-Releasing Hormone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-resistant Prostate Cancer × Docetaxel × Clear all
NCT05762536 2024-06-27

DAROTAXEL

Erasmus Medical Center

Phase 2 Recruiting
245 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04586543 2020-10-14

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

University of Pecs

Phase 2 Unknown
110 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡